Tens of billions of antithrombotic drugs have fallen into the "Altar"! TOP10 ranking changes

A few days ago, Yangtze River Jiangsu Zilong Pharmaceutical's Fondaparinux Sodium Injection was approved as a supplementary application, and it is the fourth company that has reviewed the product
.
In addition, Changzhou Pharmaceutical's rivaroxaban tablets and Beijing Baiao's apixaban tablets have all entered administrative approval and are expected to be approved.
.
.
the antithrombotic drug market will make waves again
.
According to data from Meinenet, the market for terminal antithrombotic drugs in public medical institutions in China in 2021H1 increased by 13.
89% year-on-year
.
Among the TOP10 products, rivaroxaban tablets surpassed clopidogrel bisulfate tablets and won the "selling crown" throne
.
Since the beginning of this year, a total of 10 antithrombotic drugs have been approved for marketing; 23 products have been submitted for production and are under review.
No domestic companies have been approved for clopidogrel bisulfate aspirin tablets and prasugrel hydrochloride tablets, and idoxaban tosylate No generic drugs have been approved, including Nanjing Chia Tai Tianqing Pharmaceutical, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceuticals and other companies
.
Soaring 130% injections, Yangtze River commented! The 30 billion market is making waves again.
The sales of fondaparinux sodium injection in public medical institutions in China (unit: 100 million yuan).
Source: Menet.
com.
The competitive landscape of Chinese public medical institutions.
Recently, the fondaparinux sodium from Yangtze River Jiangsu Zilong Pharmaceutical The injection was approved as a supplementary application, and it was the fourth company to have reviewed the product
.
Fondaparinux was developed by GlaxoSmithKline and sold to Aspen
.
According to data from Menet.
com, in recent years, the sales of terminal fondaparinux sodium injection in urban public hospitals, county-level public hospitals, urban community centers and township health centers (Chinese public medical institutions) have risen rapidly, with a year-on-year increase of over 130% in 2021H1.
Among them, Jiangsu Hengrui Medicine has the largest market share
.
Fondaparinux sodium injection has been evaluated by 4 companies including Jiangsu Hengrui Pharmaceutical, Yangzijiang Jiangsu Zilong Pharmaceutical, Hunan Kelun Pharmaceutical, Jilin Huisheng Biopharmaceutical|Jilin Jinsheng Pharmaceutical and other 3 companies reported as generic 4 types of production Under review and approval
.
Up to now, Yangtze River has already reviewed 4 antithrombotic drugs.
Among them, clopidogrel bisulfate tablets, rivaroxaban tablets, and ticagrelor tablets have been approved for production in 4 generic categories, which are deemed to have been reviewed.

.
In addition, four products of tirofiban hydrochloride injection, apixaban tablets, bivacrudine for injection, and ticagrelor dispersible tablets are reported for production under the new classification and are under review and approval
.
Sales of terminal antithrombotic drugs in public medical institutions in China Source: Meinenet.
In addition to Yangtze River, the terminal competition pattern of public medical institutions in China.
Changzhou Pharmaceutical’s rivaroxaban tablets and Beijing Baiao’s apixaban tablets have all entered administrative approval, which is expected Approved.
.
.
The antithrombotic drug market has made waves again
.
According to data from Mi Nei.
com, in recent years, the market for terminal antithrombotic drugs in public medical institutions in China has maintained steady growth, with a scale of more than 30 billion yuan.
In 2020, affected by the epidemic, centralized procurement and other factors, sales will decline, and in 2021H1, it will rebound, year-on-year.
An increase of 13.
89%
.
From the perspective of sales channels, the market share of county-level public hospitals and township health centers has increased
.
In terms of dosage forms, injections and tablets are mainly used, with a total market share of more than 95%
.
From the perspective of TOP10 manufacturers, the top three are foreign-funded pharmaceutical companies.
Bayer's market share will surpass Sanofi in 2020, ranking first, and continue to grow in 2021H1; domestic pharmaceutical companies include Hebei Changshan Biochemical Pharmaceutical and Lepu 5 companies including Sinopharm and CSPC Ouyi Pharmaceutical
.
Tens of billions of antithrombotic drugs fell into the "Altar"! TOP10 ranking changes 2021H1 China's public medical institutions' terminal antithrombotic drug products TOP10 Source: Meinnet.
com China's public medical institutions' terminal competition pattern product TOP10, the top five sales exceeded 1 billion yuan, of which rivaroxaban tablets surpassed sulfuric acid Hydroclopidogrel tablets won the "sales crown" throne; from the perspective of sales growth rate, rivaroxaban tablets have the fastest growth rate, exceeding 50%; enoxaparin sodium injection, nadroparin calcium injection, Darby The growth rate of Gattrex capsules exceeded 20%; only clopidogrel bisulfate tablets had negative growth
.
2021H1 China's top 10 public medical institutions' terminal antithrombotic drug brands Source: Meinnet.
com Among the top 10 brands of China's public medical institutions' terminal competition pattern, Bayer and Sanofi each have two brands on the list, Bayer's rivaroxaban and aspirin intestines Dissolving tablets occupy the first and second positions, and Sanofi's clopidogrel bisulfate tablets are the only brand that has declined
.
In terms of growth rate, Bayer's rivaroxaban tablets are the fastest, followed by CSPC Ouyi Pharmaceutical's clopidogrel bisulfate tablets and Sanofi's enoxaparin sodium injection
.
Sales of Clopidogrel Hydrogen Sulfate Tablets in China's Public Medical Institutions (Unit: 100 million yuan) Source: Mynet.
com.
China's public medical institutions terminal competition pattern.
Up to now, the five batches of national procurement have a total of clopidogrel bisulfate tablets and apixaban tablets.
Six antithrombotic drugs, ticagrelor tablets, bivacrudine for injection, dabigatran etexilate capsules, and rivaroxaban tablets, were shortlisted.
Bivarrudine for injection was the only antithrombotic injection that entered the collection.
Ticagrelor tablets ranked sixth in the TOP10 terminal antithrombotic drug products of China's public medical institutions in 2020, and fell out of the top ten in 2021H1
.
Among the TOP10 products, three are centralized procurement.
Among them, clopidogrel bisulfate tablets, as a tens of billions of varieties, were first included in centralized procurement.
The peak sales appeared in 2018, and there was a slight decline in 2019, and a year-on-year decline in 2020.
Nearly 60%, 2021H1 fell 4.
01% year-on-year; rivaroxaban tablets and dabigatran etexilate capsules are the fifth batch of collectively harvested varieties, and rivaroxaban tablets are the most competitive, with as many as 13 bidding companies, and the future market structure Mi Nei.
com will continue to pay attention to any changes
.
Three major products have become "flavored pastries", Nanjing Chia Tai Tianqing, Yangtze River.
.
.
Be the first to imitate anti-thrombotic drugs approved for marketing since 2021.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database This year, there are a total of 10 Antithrombotic drugs have been approved for marketing.
Among them, rivaroxaban tablets have the largest number of approved companies, with 19 companies, followed by ticagrelor tablets with 11 companies, and apixaban tablets with 10 companies
.
In addition, Wuhan Hengxinyuan Pharmaceutical's ozagrel tromethamine injection concentrated solution was approved as a new drug category 2.
1, and it was the first domestically produced enterprise of the product; Tianjin Hongri Pharmaceutical's sagogrelide hydrochloride tablets was the "first imitation".
+The first review"
.
The source of antithrombotic drugs that have been reported for production and under review since 2021: Meinenet MED2.
0 Chinese Drug Evaluation Database There are 23 antithrombotic drugs that are under review and approval, with more than 80 acceptance numbers
.
Among them, Argatroban injection and rivaroxaban tablets are the most sought-after, with 9 companies each
.
In addition, clopidogrel bisulfate aspirin tablets and prasugrel hydrochloride tablets have not been approved by domestic companies, and 4 such as idoxaban tosylate tablets, selepag tablets and ticagrelor dispersible tablets have no generic drugs.
Approved, involving Nanjing Chia Tai Tianqing Pharmaceutical, Jiangsu Haosen Pharmaceutical Group, Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical and other companies
.
Source: Mi Neiwang database If there are any errors or omissions, please correct me
.